Search clinical trials for: Xarelto

Total 252 results

Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Bayer

Completed

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort (OSCAR-US)

Treatment of Venous Thromboembolism in Cancer Patients | Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

United States
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (BROTHER)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer

Completed

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs (XATOC)

Coronary Artery Disease | Peripheral Artery Disease

Spain, Belgium, Italy, Korea, Republic of, Russian Federation, Taiwan, China, Colombia, Switzerland, Slovenia
Massachusetts General Hospital

Completed

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation (NEW-AF)

Stroke | Atrial Fibrillation | Bleeding

United States
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute

Completed

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)

Cancer | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Blood Clot

United States
Maatschap Cardiologie Zwolle
Diagram B.V.

Completed

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

Coronary Artery Disease (CAD) | Peripheral Arterial Disease (PAD)

Netherlands
Population Health Research Institute

Completed

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Ischemic Stroke | Intracranial Atherosclerotic Disease

Canada
Bayer

Completed

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Venous Thrombosis | Deep Vein Thrombosis

Belgium, Israel, Italy, Spain, Switzerland, Colombia, New Zealand, Hungary, Canada, Sweden, Austria, Czechia, Germany, Poland, Netherlands, Peru, South Africa, Australia, Brazil
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (APERITIF)

Myocardial Infarction, Acute | Left Ventricular Thrombus

France
Brigham and Women's Hospital

Completed

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

Deep Vein Thrombosis, Pulmonary Embolus

United States
Brigham and Women's Hospital

Completed

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
Brigham and Women's Hospital

Completed

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism | Pulmonary Embolism | DVT

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto [SPAF] Post-marketing Surveillance in Japan

Brain Ischemia

Japan
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis

Mild Cognitive Impairment

China
Bayer
Janssen Research & Development, LLC

Completed

Real-world Dosing Patterns of Rivaroxaban in the United States

Atrial Fibrillation

United States
Fundación de Investigación Biomédica - Hospital...

Active, not recruiting

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Atrial Fibrillation

Spain
Ottawa Heart Institute Research Corporation
Bayer; Canadian Institutes of Health Research (CIHR); Biotronik Canada Inc

Active, not recruiting

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)

Stroke | Atrial Fibrillation

Canada, Australia, Germany, Belgium, China, Israel
GWT-TUD GmbH
Bayer

Completed

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Superficial Vein Thrombosis

Germany
University of Florida
Janssen, LP

Completed

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease (SWAP-AC)

Coronary Artery Disease

United States
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Completed

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI (REWARF-STEMI)

ST Segment Elevation Myocardial Infarction | Left Ventricular Thrombus

Iran, Islamic Republic of
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
University of Alberta

Completed

Rivaroxaban in Type 2 Myocardial Infarctions (R2MI)

Type II Myocardial Infarction

Canada
Eli Lilly and Company

Completed

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

Healthy

United States
Laval University

Withdrawn

DOAC Versus VKA After Cardiac Surgery (DOAC/VKA)

Anticoagulant-induced Bleeding

Canada
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Bayer

Completed

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Treatment of Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
University of British Columbia

Completed

Study of Rivaroxaban for CeREbral Venous Thrombosis (SECRET)

Cerebral Venous Thrombosis

Canada
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism) (H2H-OSCAR-US)

Cancer | Venous Thromboembolism | Treatment of Venous Thromboembolism in Cancer Patients

Germany
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Terminated

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (VERDICT)

Renal Insufficiency

France
Population Health Research Institute
Bayer; University of Cape Town

Completed

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (INVICTUS-VKA)

Rheumatic Heart Disease

Botswana, Philippines, Zimbabwe, India, China, Egypt, Ethiopia, Uganda, Brazil, South Africa, Cameroon, Tanzania, Kenya, Zambia, Kazakhstan, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Rwanda, Sudan
University of Karachi
Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research... and other collaborators

Completed

Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions (Bioequivalence)

Bioequivalence

Pakistan
Instituto Mexicano del Seguro Social

Completed

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Venous Thromboembolism | Pulmonary Embolism | Anticoagulant-induced Bleeding | Venous Thromboses

Mexico
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Assistance Publique - Hôpitaux de Paris

Completed

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (RIPORT)

Deep Vein Thrombosis | Chronic Portal Vein Thrombosis

France
Population Health Research Institute
University of Cape Town

Withdrawn

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority (INVICTUS-ASA)

Rheumatic Heart Disease
University of Florida
Janssen Scientific Affairs, LLC

Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Coronary Artery Disease | Peripheral Arterial Disease | Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands

Search clinical trials for: Xarelto

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations